Management of Postoperative Residual Disease after Neoadjuvant Therapy and Surgery in Esophageal Cancer: Maximizing the Options

摘要

The optimal management of locally advanced esophageal cancer remains a subject of active debate. Despite controversy, there is now consensus that surgery alone is inadequate therapy for patients with T3 or node-positive disease. Increasingly, patients with esophagogastric cancer are treated with preoperative chemotherapy (the more common European approach) or combined chemoradiotherapy (the more common U.S. approach). Limited studies have been undertaken in esophageal cancer of postoperative adjuvant therapy, or of additional postoperative treatment after preoperative therapy.